Efficacy and Safety of LAMA/LABA Fixed-Dose Combination Therapies in Chronic Obstructive Pulmonary Disease: A Systematic Review of Direct and Indirect Treatment Comparisons

References

• GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1736–1788.30496103
   PubMed Web of Science ®Google Scholar
• GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1789–1858.30496104
   PubMed Web of Science ®Google Scholar
• World Health Organization. Chronic obstructive pulmonary disease (COPD) fact sheet; 2017 Available from: https://www.who.int/en/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd). Accessed 1221, 2017.
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. 2020 report: global strategy for the diagnosis, management and prevention of COPD; 2020 Available from: https://goldcopd.org. Accessed 317, 2020.
   Google Scholar
• BogartM, StanfordRH, LalibertéF, GermainG, WuJW, DuhMS. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population. Int J Chron Obstruct Pulmon Dis. 2019;14:343–352.30863037
   PubMed Web of Science ®Google Scholar
• YuAP, GuérinA. Ponce de LeonD, et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ. 2011;14(4):486–496.21679019
   PubMedGoogle Scholar
• GlaxoSmithKline (Ireland) Limited. Anoro Ellipta summary of product characteristics; 2019 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002751/WC500168424.pdf. Accessed 411, 2019.
   Google Scholar
• AstraZenecaAB Duaklir Genuair summary of product characteristics; 2017 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003745/WC500178413.pdf. Accessed 411, 2019.
   Google Scholar
• Novartis Europharm Limited. Ultibro Breezhaler summary of product characteristics; 2017 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002679/WC500151255.pdf. Accessed 411, 2019.
   Google Scholar
• Boehringer Ingelheim International GmbH. Spiolto Respimat summary of product characteristics; 2019 https://www.medicines.org.uk/emc/product/6902. Accessed 117, 2020.
   Google Scholar
• AstraZeneca PharmaceuticalsLP Bevespi Aerosphere™ prescribing information; 2019 http://www.azpicentral.com/bevespi/bevespi_pi.pdf. Accessed 72, 2019.
   Google Scholar
• UsmaniOS. Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag. 2019;15(14):461–472.30936708
   PubMed Web of Science ®Google Scholar
• RileyRD, JacksonD, SalantiG, et al. Multivariate and network meta-analysis of multiple outcomes and multiple treatments: rationale, concepts, and examples. BMJ. 2017;358:j3932.28903924
   PubMed Web of Science ®Google Scholar
• MadanJ, StevensonMD, CooperKL, AdesAE, WhyteS, AkehurstR. Consistency between direct and indirect trial evidence: is direct evidence always more reliable? Value Health. 2011;14(6):953–960.21914518
   PubMed Web of Science ®Google Scholar
• SiddiquiM, ShuklaP, JenkinsM, et al. Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β2-agonist fixed-dose combinations in COPD. Ther Adv Respir Dis. 2019;13:1753466619894502.31868101
   PubMed Web of Science ®Google Scholar
• JansenJP, TrikalinosT, CappelleriJC, et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC good practice task force report. Value Health. 2014;17(2):157–173.24636374
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on the clinical investigation of medicinal products for the treatment of chronic obstructive pulmonary disease (COPD); 2012 Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-chronic-obstructive-pulmonary-disease_en.pdf. Accessed 325, 2019.
   Google Scholar
• MaltaisF, FergusonGT, FeldmanGJ, et al. A randomized, double-blind, double-dummy study of glycopyrrolate/formoterol fumarate metered dose inhaler relative to umeclidinium/vilanterol dry powder inhaler in COPD. Adv Ther. 2019;36(9):2434–2449.31267366
   PubMed Web of Science ®Google Scholar
• KerwinE, FergusonGT, SanjarS, et al. Dual bronchodilation with indacaterol maleate/glycopyrronium bromide compared with umeclidinium bromide/vilanterol in patients with moderate-to-severe COPD: results from two randomized, controlled, cross-over studies. Lung. 2017;195(6):739–747.28993871
   PubMed Web of Science ®Google Scholar
• FeldmanGJ, SousaAR, LipsonDA, et al. Comparative efficacy of once-daily umeclidinium/vilanterol and tiotropium/olodaterol therapy in symptomatic chronic obstructive pulmonary disease: a randomized study. Adv Ther. 2017;34(11):2518–2533.29094315
   PubMed Web of Science ®Google Scholar
• RoglianiP, Matera MG, Ritondo BL, et al. Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. Pulm Pharmacol Ther. 2019;59:101841.31520718
   PubMed Web of Science ®Google Scholar
• AzizMIA, TanLE, WuDB, et al. Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:3203–3231.30349228
   PubMed Web of Science ®Google Scholar
• SionKYJ, HuismanEL, PunekarYS, NayaI, IsmailaAS. A network meta-analysis of long-acting muscarinic antagonist (LAMA) and long-acting β2-agonist (LABA) combinations in COPD. Pulm Ther. 2017;3(2):297–316.32026346
   PubMedGoogle Scholar
• SchlueterM, Gonzalez-RojasN, BaldwinM, GroenkeL, VossF, ReasonT. Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis. Ther Adv Respir Dis. 2016;10(2):89–104.26746383
   PubMed Web of Science ®Google Scholar
• HuismanEL, CockleSM, IsmailaAS, KarabisA, PunekarYS. Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2015;10:1863–1881.26392761
   PubMed Web of Science ®Google Scholar
• ToninFS, RottaI, MendesAM, PontaroloR. Network meta-analysis: a technique to gather evidence from direct and indirect comparisons. Pharm Pract. 2017;15(1):943.
   PubMed Web of Science ®Google Scholar
• JonesPW, BeehKM, ChapmanKR, DecramerM, MahlerDA, WedzichaJA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250–255.24383418
   PubMed Web of Science ®Google Scholar
• AgustiA, CalverleyPM, CelliB, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122.20831787
   PubMed Web of Science ®Google Scholar
• BattistiWP, WagerE, BaltzerL, et al. Good publication practice for communicating company-sponsored medical research: GPP3. Ann Intern Med. 2015;163(6):461–464.26259067
   PubMed Web of Science ®Google Scholar